The stock of healthcare behemoth Abbott Laboratories (NYSE: ABT ) has experienced an uninspiring 2024 so far; in a year where the prime equity bellwether has generated solid returns of 23%, and even the healthcare cohort of the S&P 500Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensati ...